宇邦新材(301266.SZ):擬投約5億元建設年產光伏焊帶20000噸生產項目
格隆匯1月18日丨宇邦新材(301266.SZ)公佈,公司於2023年1月18日召開第三屆董事會第十二次會議和第三屆監事會第十次會議,審議通過《關於公司與安徽和縣經濟開發區管理委員會簽署投資協議暨對外投資的議案》,為持續推進公司的總體發展戰略,進一步完善公司產能佈局,滿足客户產能配套需求,提升公司的行業影響力和綜合競爭力,同意公司與安徽和縣經濟開發區管理委員會(簡稱“甲方”)簽署《投資協議書》,擬在安徽和縣經濟開發區投資建設年產光伏焊帶20000噸生產項目,由公司全資子公司安徽宇邦新型材料有限公司負責該項目的實施。項目計劃總投資約5億元,將根據項目的實施計劃分期實施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.